Last reviewed · How we verify
NCT04205032: CDSII
Evaluation in Healthy Volunteers of CARDIOSPACE II
NA trial testing Test of the different devices integrated in cardiospace II in Healthy in 4 participants. Completed in 8 July 2021.
2 July 2021
Quick facts
| Lead sponsor | University Hospital, Angers |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 4 |
| Start date | 28 June 2021 |
| Primary completion | 2 July 2021 |
| Estimated completion | 8 July 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Test of the different devices integrated in cardiospace II
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
University Hospital, Angers
Who can join
Adults 18 to 45, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this project is to test the CARDIOSPACE II system that integrates several medical devices. This system is dedicated to physiological studies in space environment. * Electrocardiogram * Vascular doppler * Laser doppler with iontophoresis * Continuous blood pressure recording at the finger level * Brachial blood pressure * Ultrasound * Ambulatory Electrocardiogram and SAO2 (arterial oxygen saturation) recorder
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04205032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other University Hospital, Angers trials
Trials by the same sponsor.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07470294 — Effectiveness of Different Surgical Techniques for Curative Treatment of Pilonidal Sinus Disease in the Pediatric Popula · not yet recruiting
- NCT07409597 — Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease · NA · not yet recruiting
- NCT07468565 — Surgical Approach for the Treatment of Hirschsprung Disease Using the Swenson Technique (SMILES) · not yet recruiting
- NCT07452952 — Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distre · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04205032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Angers
- Last refreshed: 28 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04205032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing